Form 4: Moderna Executive Stephen Hoge Reports Stock Option Grant and RSU Acquisition

Moderna's President, Stephen Hoge, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC Form 4 filing.

Summary

• Stephen Hoge, President of Moderna, Inc., filed a Form 4 with the SEC on February 29, 2024.
• The filing reports transactions occurring on February 27, 2024.
• Hoge acquired 43,894 stock options with an exercise price of $96.20, vesting quarterly starting February 27, 2025, and expiring on February 27, 2034.
• He also acquired 22,987 restricted stock units (RSUs), vesting quarterly starting February 27, 2025.
• Hoge directly owns 1,513,433 shares of Moderna common stock.
• He indirectly owns 4,116 shares through Valhalla, LLC and 151,933 shares through a trust for the benefit of his spouse and children.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs to a key executive suggests confidence in the company's future, but it's a routine event.

Positives

• The acquisition of stock options and RSUs by a key executive like Stephen Hoge can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule aligns the executive's interests with the long-term success of the company.

Industry Context

Executive compensation in the biotechnology industry often includes stock options and RSUs to incentivize performance and align executive interests with shareholder value. This filing reflects a standard practice in the industry.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the biotech industry, used by companies like Pfizer, BioNTech, and Johnson & Johnson.
• The vesting schedules, typically quarterly or annually, are designed to retain talent and incentivize long-term performance, aligning with industry norms.
• The size of the grant is relative to the executive's role and the company's overall compensation strategy, which is competitive within the biotech sector.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs as a positive sign, aligning management's interests with their own.
• Employees may see this as a sign of stability and potential future growth for the company.

Key Dates